65th American Society of Hematology Annual Meeting and Exposition (ASH 2023)

The hepcidin mimetic rusfertide provides long-term control of haematocrit (2.5 years) and reduces the use of phlebotomy among patients with polycythemia vera (PCV) in the phase II REVIVE study

The anti–CSF-R1 antibody axatilimab offers rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (GVHD) in the pivotal phase II AGAVE-201 trial.

In the primary analysis of the expanded-access ZUMA-18 trial, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) demonstrated a high level of efficacy in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Daily treatment with the immunomodulatory agent pomalidomide for 6 months significantly reduced severe nosebleeds in patients with hereditary haemorrhagic telangiectasia (HHT) in the double-blind, randomized, placebo-controlled PATH-HHT trial.

The full analysis of the phase III COMMANDS trial continues to demonstrate the superiority of luspatercept over epoetin alfa for the treatment of erythropoiesis-stimulating agent (ESA)-naïve patients with transfusion-dependent lower-risk myelodysplastic syndromes (TD LR-MDS).

A single infusion of lovotibeglogene autotemcel (lovo-cel) resulted in near-complete resolution of vaso-occlusive events (VOEs) among patients with sickle cell disease (SCD), according to the combined analysis of phase I/II HGB-206 group C and phase III HGB-210 studies presented at ASH 2023.

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.

The novel, investigational anti-tissue factor pathway inhibitor marstacimab outdid factor replacement therapy (FRT) in reducing bleeds in patients with severe haemophilia A (HA) or moderately severe to severe haemophilia B (HB) without inhibitors beyond 12 months in the phase III BASIS trial.